Welcome to our dedicated page for Alpha Tau Medical Ltd. Warrant news (Ticker: DRTSW), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical Ltd. Warrant stock.
Alpha Tau Medical focuses on research, development, and commercialization of Alpha DaRT for solid cancer tumor treatment. Utilizing alpha radiation, Alpha DaRT aims to provide highly potent and conformal radiotherapy by treating solid tumors with interstitial radioactive seeds.
Rhea-AI Summary
Alpha Tau Medical announced that CFO Raphi Levy will present at investor conferences in May 2024. The company, known for its alpha-radiation cancer therapy Alpha DaRT™, will participate in events like Guggenheim Securities Radiopharmaceuticals Day and H.C. Wainwright BioConnect Investor Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
-
Rhea-AI Summary
Alpha Tau Medical announces CFO Raphi Levy's presentation at the Jefferies Radiopharma Innovation Summit on April 11th, 2024, to provide a corporate overview and update on Alpha DaRT™, the innovative alpha-radiation cancer therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
-
Rhea-AI Summary
Alpha Tau Medical Ltd. reported positive interim safety and feasibility data from a pancreatic cancer study in Montreal, entered a pivotal U.S. trial, submitted a PMDA application in Japan, and expanded its U.S. facility. The company has a strong financial position with $84.9 million in cash, providing a runway for at least two years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
Rhea-AI Summary
Alpha Tau Medical Ltd. (NASDAQ: DRTS) will participate in the Barclays 26th Annual Global Healthcare Conference to showcase its innovative alpha-radiation cancer therapy Alpha DaRT™ on March 12th and 13th, 2024, in Miami, FL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
-
Rhea-AI Summary
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) announced Chairman and CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The Company will also be featured at the Biotech Showcase occurring in parallel, with plans to present on January 8, 2024. Alpha Tau has achieved highly promising interim results from the pancreatic cancer safety and feasibility trial, along with robust long-term data analyzed across four clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
-
Rhea-AI Summary
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) will present at the Sidoti Small-Cap Virtual Conference on December 7th, 2023, to showcase their innovative alpha-radiation cancer therapy Alpha DaRT™.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
Rhea-AI Summary
Alpha Tau Medical Ltd. (DRTS) announced interim results from the treatment of the first five patients in the safety and feasibility trial using Alpha DaRT to treat advanced pancreatic cancer. The data showed successful delivery in all cases, with no product-related Serious Adverse Events. The first five patients received conservative partial tumor coverage, and increased tumor responses were observed in patients with higher radium-224 levels. The CEO expressed optimism about the results exceeding expectations. The principal investigator noted the ease of use and accuracy in delivering Alpha DaRT sources into the pancreas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
-
Rhea-AI Summary
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) and HekaBio K.K. announced that Japan’s Pharmaceuticals and Medical Devices Agency has accepted Alpha Tau’s submission for pre-market approval of Alpha DaRT in patients with recurrent head & neck cancer. This submission is based on clinical trial results that exceeded safety and efficacy endpoints, with discussions underway for a potential commercial partnership in Japan. CEO Uzi Sofer highlighted the strategic importance of Japan as a market, while CEO Rob Claar emphasized the potential impact on patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
-
Rhea-AI Summary
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) reported treating the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel. They also provided an update on safety and feasibility trials, financial results, and corporate highlights. Former U.S. FDA Commissioner, Stephen M. Hahn, M.D. has been appointed to Alpha Tau Scientific Advisory Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags
Rhea-AI Summary
Alpha Tau Medical Ltd. announced that it will participate in several investor conferences in November 2023, including the Emerging Growth Conference, Jefferies London Healthcare Conference, and Piper Sandler 35th Annual Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
FAQ
What is the current stock price of Alpha Tau Medical Ltd. Warrant (DRTSW)?
The current stock price of Alpha Tau Medical Ltd. Warrant (DRTSW) is $0.176 as of November 1, 2024.
What is Alpha Tau Medical Ltd. focused on?
Alpha Tau Medical is focused on research, development, and commercialization of Alpha DaRT for treating solid cancer tumors.
What technology does Alpha DaRT utilize?
Alpha DaRT uses alpha radiation to deliver highly potent and conformal radiotherapy to solid tumors.
What are the primary goals of Alpha DaRT technology?
The primary goals include treating solid tumors with interstitial radioactive seeds that release short-lived alpha emitting atoms into the tumor.
What recent achievements has Alpha Tau Medical reported?
Alpha Tau Medical reported successful delivery in all five cases of its first clinical trial and observed increased tumor responses in patients with higher radium-224 levels.
What clinical trial is Alpha Tau Medical currently running?
Alpha Tau Medical is running a safety and feasibility trial to treat advanced pancreatic cancer with Alpha DaRT at two university hospitals in Montreal, Canada.
What is the significance of the breakthrough technology used by Alpha Tau Medical?
The breakthrough technology utilizes alpha radiation to deliver highly potent and conformal radiotherapy for the treatment of solid tumors.
What are some upcoming milestones for Alpha Tau Medical in 2024?
Alpha Tau Medical plans to report financial results for the quarter ended March 31, 2024, and continue advancing its clinical trials to broaden the use of Alpha DaRT across various indications.
Alpha Tau Medical Ltd. Warrant